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Abstract
Background: Systemic chemotherapy for stage IV colorectal cancer has advanced markedly in the recent years.
We report an unusual case of 13 synchronous liver metastases for which a pathological complete response was
achieved with neoadjuvant chemotherapy (NAC) consisting of a combination of 5-fluorouracil (5-FU), oxaliplatin,
leucovorin (mFOLFOX6), and bevacizumab.
Case presentation: A 44-year-old man was diagnosed with colorectal cancer with synchronous liver metastases.
We resected the primary rectal tumor first. Further, after providing NAC for hepatic metastases, lateral segmentectomy
and partial resection of the liver were performed. The subsequent result was compatible with a complete pathological
response. The postoperative course was uneventful, and the patient is currently alive 5 years after the first surgery
without evidence of recurrence and without adjuvant chemotherapy.
Conclusions: For patients with initially resectable colorectal liver metastases, the survival benefits of NAC are still
unclear. We report a rare case of 13 synchronous liver metastatic lesions from rectal cancer with a complete
pathological response after neoadjuvant bevacizumab-containing chemotherapy.
Keywords: Liver metastases, Rectal cancer, Neoadjuvant chemotherapy
Background
Systemic chemotherapy for stage IV colorectal cancer
has advanced markedly in recent years following the
clinical introduction of two powerful cytotoxic anticancer
drugs [1] and molecular-targeted drugs [2, 3]. The tumor
response for colorectal liver metastasis (CRLM) has im-
proved with modern combination chemotherapy regimens.
Two distinct strategies for preoperative chemotherapy
for CRLM have emerged: neoadjuvant and conversion
chemotherapy. Neoadjuvant chemotherapy (NAC) refers
to the administration of preoperative chemotherapy for
initially resectable CRLM. Although the role of NAC
in patients with initially resectable CRLM is still con-
troversial, objectives of this approach include reducing
the tumor size, controlling any micrometastases, and
avoiding liver surgery in those with rapidly progressive
disease.
We report herein an unusual case with 13 liver me-
tastases for which a pathological complete response
was achieved with NAC consisting of a combination of
5-fluorouracil (5-FU), oxaliplatin, leucovorin (mFOL-
FOX6), and bevacizumab, although the patient was
considered to have a progressive disease during preoperative
chemotherapy.
Case presentation
A 44-year-old man was accidentally found to have positive
fecal occult blood tests on a regular checkup; therefore, he
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visited a local hospital for further examination. Colonos-
copy showed a type 2 tumor, 34 × 27 mm in size, in the
rectum (Fig. 1a). Then, the patient was referred to our
hospital for treatment.
Contrast-enhanced computed tomography (CT) showed
two hepatic metastases in segments II and IV. We planned
to resect the primary rectal tumor first, followed by liver
resection. The patient underwent low anterior resection of
the rectum, and the resected specimen was a type 2 tumor
of the rectum (Fig. 1b). Histological examination of the
resected rectum showed mucinous adenocarcinoma (mp,
ly2, v0, N1 [1/28]) (Fig. 1c). Contrast-enhanced CT images
obtained 1 month postoperatively showed an increase in
the number of liver metastases from 2 to 12 lesions. Al-
though it was possible to resect all the metastatic lesions
in the liver, we planned to perform hepatectomy following
NAC because the disease was rapidly progressive.
After 6 cycles of mFOLFOX6 plus bevacizumab, a
major response of the liver metastases was documented
by using CT. All metastases in the liver decreased in
size, and the tumor morphology changed from heteroge-
neous attenuation, a variable degree of enhancement, and
ill-defined borders before treatment to homogeneous,
hypoattenuation with well-defined borders (Figs. 2 and 3).
However, we evaluated the progression of the disease be-
cause the number of metastases increased from 12 before
NAC to 13 after 6 cycles of chemotherapy, although
the metastases were potentially resectable at this time.
Therefore, we added six more cycles of mFOLFOX6
plus bevacizumab followed by chemotherapy consisting
of a combination of 5-FU, leucovorin, and bevacizu-
mab. Serum levels of the carcinoembryonic antigen and
cancer antigen 19-9 before chemotherapy were 21.7 ng/mL
and 746 IU/L, respectively, and they decreased to 2.8 ng/
mL and 8 IU/L before hepatectomy, respectively.
He underwent lateral segmentectomy (i.e., resection of
segments II and III) and partial resection of segments
IV, V, VI, VII, and VIII 1 year after the first operation to
confirm that the number of metastases in the liver had
not increased further.
Macroscopically, the tumor in segment II was white
and homogeneous, and it had a clear border (Fig. 4a).
Pathological examination demonstrated that all tumors
had mucin, fibrotic tissue, and no viable cancer cells
(Fig. 4b). These findings were compatible with a complete
pathological response. His postoperative course was un-
eventful, and he is currently alive 5 years after the first sur-
gery without evidence of recurrence despite no adjuvant
chemotherapy.
Discussion
We reported herein a rare case of 13 synchronous liver
metastatic lesions from rectal cancer with a complete
pathological response after neoadjuvant bevacizumab-
containing chemotherapy. Another unusual feature of
the case was that the response evaluation on CT after
6 cycles of chemotherapy indicated a progressive disease
because a new lesion (the 13th lesion) emerged in the
liver.
For patients with initially resectable CRLM, the survival
benefit of NAC is still unclear. Potential disadvantages of
NAC are the inherent risk of disease progression pre-
operatively and the risk of liver toxicity. The routine use of
NAC for patients with clearly resectable lesions limited to
the liver is not recommended owing to a lack of benefit
on survival [4].
However, both imaging and pathological responses of
liver metastases to preoperative chemotherapy are good
prognostic variables [5, 6]. NAC is most beneficial when
patients with favorable tumor biology are identified and
selected for treatment [6].
A complete radiological response was achieved in 3
to 14 % of patients in the neoadjuvant setting with cyto-
toxic chemotherapy (oxaliplatin-based or irinotecan-based
chemotherapy) for CRLM [7–10]. Even in patients with
no metastases observed on imaging, residual macroscopic
disease was found in about 25 to 45 % of the patients at
the time of operation [11–14]. In patients with no obvious
disease at surgery, microscopic cancer was observed in the
resected specimen from the site of initial liver metastases
in 80 % of the patients. In addition, in patients with no tu-
mors observed and in whom the site of complete response
was left in place, in situ recurrence was observed in 74 %
of the cases after 1 year [13]. Therefore, a complete
response on imaging does not necessarily equate with a
complete clinical or pathological response [13, 14]. A
pathological complete response was achieved in 2 to
a b
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Fig. 1 Colonoscopic, macroscopic, and histological findings.
a Colonoscopy showing a type 2 tumor. b Macroscopic findings
of the resected rectum. c Histological examination of the primary
tumor showing mucinous adenocarcinoma
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11 % of the patients with only cytotoxic chemotherapy
[5, 8, 15].
Bevacizumab is the only anti-angiogenic agent that has
been extensively studied in the setting of resectable (or
potentially resectable) or unresectable CRLM. Although
the complete radiological response rate in patients treated
with bevacizumab-containing regimens ranges from 0 to
9 % [16–18], a pathological complete response has been
achieved in 8.9 to 16 % of the patients [14, 15, 19].
The discrepancy between radiological and pathological
complete response rates may be because of the cytostatic
mechanism of bevacizumab. Response evaluation criteria
for solid tumors are standard measures used to evaluate
the tumor response to treatment; they were developed to
Fig. 2 Contrast-enhanced computed tomographic image 1 month after the first operation. The number of liver metastases increased from 2 to 12 lesions
Fig. 3 Contrast-enhanced computed tomographic image after 6 cycles of neoadjuvant chemotherapy. The 12 tumors detected before
chemotherapy have decreased in size and have had an optimal morphological response. However, a new lesion has emerged in segment VIII
of the liver (arrowhead)
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assess tumor shrinkage after cytotoxic chemotherapy.
However, the criteria may be limited in assessing the
response to bevacizumab-containing chemotherapy [19].
Chun et al. demonstrated that CRLMs tend to decrease in
size and display unique morphological changes in CT
images after bevacizumab-containing chemotherapy. They
defined an optimal morphologic response on contrast-
enhanced CT images as a change in metastases from
lesions with heterogeneous attenuation and thick, irregu-
lar borders to homogeneously hypodense masses with a
sharp interface between the tumor and adjacent normal
liver parenchyma, which in some cases can mimic a cyst
[19]. Effective morphological changes correspond to the
replacement of tumor cells by fibrosis, pathologically [19].
The optimal timing of primary tumor and liver metas-
tases resection in patients with synchronous resectable
CRLM is still controversial. Our strategy has been to
perform resection of the primary colorectal tumor first
followed by hepatectomy (i.e., staged resection). The
patient was treated with NAC for synchronous liver
metastases following the resection of primary cancer
because the number and size of liver metastases had
rapidly increased before the planned hepatectomy.
On contrast-enhanced CT performed after 6 cycles of
bevacizumab-containing chemotherapy, all the 12 liver
metastases detected before chemotherapy had decreased
in size, and radiological findings of the metastases
showed effective signs corresponding to the optimal
morphologic response [19]. However, we evaluated it as
a progressive disease because a new lesion emerged in
the liver. The reason why the new lesion, which conse-
quently showed a pathological complete response, was
detectable after chemotherapy is unclear. The lesion that
was in situ before chemotherapy may have become de-
tectable in CT images owing to its modification to a
homogeneous, hypoattenuating lesion with well-defined
borders due to the effect of bevacizumab-containing
chemotherapy. As a result, the time when the 6 cycles of
chemotherapy are completed may be the optimal timing
for hepatectomy. As in the present case, it is necessary to
evaluate the effectiveness of the treatment carefully when
the number of tumors increases during bevacizumab-
containing chemotherapy and the optimal morphologic
response is identified.
Complete pathologic clearance of all liver metastases
after chemotherapy is associated with considerable overall
survival, and it is a strong predictor of both prolonged
survival and disease cure [5]. Several retrospective studies
have demonstrated that in patients with a good patho-
logical response to NAC, adding bevacizumab to the
cytotoxic drugs was associated with a better outcome
[20–22]. The patient reported herein with more than
10 synchronous liver metastases is alive without recur-
rence for 4 years since the last operation, and we believe
that the disease is cured.
Conclusions
In conclusion, the survival benefits of NAC are still
unclear for patients with initially resectable colorectal
liver metastases. We report a rare case of 13 synchronous
liver metastatic lesions from rectal cancer with a complete




Fig. 4 Microscopic and histological findings. a Microscopic findings of the resected specimen of the liver (S2). The tumor is white and
homogeneous. The boundary between the non-cancerous parts is clear. b Histological findings of the tumor show the absence of mucinous
adenocarcinoma cells and the presence of only mucous
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